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Abstract
Background: Genital mucosae play a key role in protection from STD and HIV infection, due to their involvement in both
horizontal and vertical disease transmission. High variability of published observations concerning IgA isolation and
quantification underlies the strong requirement of specific methods able to maximize investigation on HIV-specific IgA.
Methodology: Genital fluids from 109 subjects, including male and female cohorts from Italy and Cambodia, were collected,
aliquoted and processed with different techniques, to assess optimal conditions maximizing mucosal antibody recovery.
Three sampling techniques, up to sixteen preservation conditions, six ELISA methods and four purifications protocols were
compared.
Principal Findings: The optimal method here described took advantage of Weck-Cel sampling of female mucosal fluids.
Immediate processing of genital fluids, with the addition of antibiotics and EDTA, improved recovery of vaginal IgA, while
the triple addition of EDTA, antibiotics and protease inhibitors provided the highest amount of seminal IgA. Due to low
amount of IgA in mucosal fluids, a high sensitive sandwich ELISA assay was set; sensitivity was enhanced by milk-based
overcoating buffer and by a two-step biotin-streptavidin signal amplification. Indeed, commercial antisera to detect human
immunoglobulins showed weak cross-reactivity to different antibody types. Three-step affinity purification provided
reproducible immunoglobulin recovery from genital specimens, while conventional immuno-affinity IgA purification was
found poorly manageable. Affinity columns were suitable to isolate mucosal IgA, which are ten-fold less concentrated than
IgG in genital specimens, and provided effective separation of IgA monomers, dimers, and J-chains. Jacalin-bound resin
successfully separated IgA1 from IgA2 subfraction.
Conclusions/Significance: Specific, effective and reliable methods to study local immunity are key items in understanding
host mucosal response. The sequence of methods here described is effective and reliable in analysing humoral local
responses, and may provide a solid advance to identify and measure the effective mucosal responses to HIV.
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Introduction
In the majority of cases, if not in all, HIV infection takes place
through the mucosal route, i.e. by sexual contact or child delivery
[1]. Genital mucosae are the target districts where early immune
response to HIV are likely to take place [2]; consequently, no
advance in control or prevention of the early phases of HIV
infection can be achieved without acquiring deep knowledge on
local innate and adaptive responses [3].
Several investigators have reported the induction of humoral
responses and of neutralizing antibodies to HIV, both in systemic
and in mucosal compartments, while other laboratories failed in
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protective immune response to HIV have been by far identified.
Experimental challenges with SIV and immunotherapy of HIV-
positive patients did show the effectiveness of systemic and
mucosal humoral responses, and especially that of neutralizing
antibodies [7–10]. Mucosal responses observed in HIV-positive
and HIV-exposed subjects often show great heterogeneity; this
finding may depend on individual variability or on modes of virus
exposure [3,11], but it may also reflect the intrinsic difficulty to
evaluate mucosal immunity and to measure local humoral
response.
Antibodies isolated from mucosal compartments may originate
from systemic and/or from local cells: for example, intestinal fluids
are rich in IgA from local cells, while male and female genital
fluids mostly contain IgG of systemic origin [12,13]. IgA
immunoglobulins from genital fluids present lower concentrations
than IgG, and therefore IgA can easily go undetected by standard
methods, which are optimized for serum immunoglobulins [14].
This should not be surprising, because antibody concentrations in
serum are higher than those found in mucosal secretions [15]. A
further factor complicating mucosal fluids analysis is the high
concentration of interfering proteins and glycans, which can
hamper antibodies reactivity and interfere with their isolation.
Finally, antibody concentrations in female genital fluids also
undergo cyclic variations, according with the phase of menstrual
cycle and to hormone levels [16]. Due to the low IgA
concentration in genital fluids [17] and to the concurring factors
here summarized, it is reasonable that well-working methods
suitable for IgG isolation often fail in retrieving mucosal IgA [18].
However, any investigation aimed at characterizing mucosal
immunoglobulins strongly needs specific and reliable methods to
achieve solid and reproducible results [17,19]. This study was
designed to set and validate optimal methods to isolate and
quantify IgA from a panel of HIV-positive and -negative genital
fluids.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all the participants
and for all aspects of the study, including the collection of personal
data. The study was approved by the institutional review board
from San Raffaele Scientific Institute, Milan, Italy.
Methods design and setting
The high variability of published observations concerning IgA
isolation and quantification underlines the strong requirement of a
specific method to recover, quantify and process IgA, also
applicable to the investigation of HIV-specific IgA [20,21]. The
aim of this work was therefore the design of an optimal method to
maximize quantitative IgA recovery from mucosal fluids. At this
purpose, genital fluids obtained from healthy people and from a
cohort of HIV-positive individuals were used to set and compare
analytical protocols and to validate their specificity and reliability.
Study population
Two different cohorts were studied: the former enrolled Italian
female and male subjects and the latter included Cambodian
women only. In detail, the first cohort included 23 HIV-
seropositive and 23 healthy control women, enrolled at the San
Raffaele Scientific Institute of Milan. The Italian cohort also
enrolled 33 healthy and 10 HIV-seropositive Italian men. Genital
fluids (vaginal and seminal) were obtained from healthy individuals
undergoing routinary control visits (n=23 females), subjects
undergoing assisted fertilization practices (n=33 males) and from
a cohort of HIV+ people enrolled at San Raffaele Infectious
Diseases Clinic (n=33, 23 females and 10 males). Specimens from
healthy subjects were used in the preliminary phases of the study,
to optimize and compare the effectiveness of experimental
conditions, sampling and processing methods.
The second cohort, including 10 HIV-seropositive and 10
healthy Cambodian women, was enrolled at the Pasteur Institute
of Cambodia.
All Italian seropositive patients had received antiretroviral
therapy for at least 1 year at the time of the study; CD4 cells
counts were in the range 3222745610
3 cells/mL (median 552)
and HIV plasma viraemia was ,50 copies/mL in all patients.
Female and male healthy controls were matched for age (25–45
years old) and without any known risk factor for HIV infection.
Detailed information about sexual behaviour of participants were
collected. All participants were asked to avoid sexual intercourses
24–48 hours before the sampling visit; the date of the latest
intercourse was reported and samples were controlled by optical
microscopy for the presence of spermatozoa. In order to minimize
individual variations associated with hormone levels and to
enhance antibody recovery [22], all female mucosal samples were
obtained during post-ovulatory period (i.e. collected in days 15–20
after the latest menstrual cycle, to ensure that the ovulation has
already occurred), in order to minimize individual variability of
cervicovaginal secretions that is associated with hormonal levels
and menstrual phase [16,22]. Before assaying for IgA, all samples
collected from the cohorts were incubated 30 min at 57uC. This
procedure was required to inactivate complement protein cascade,
which could interfere with testing, and to inactivate infectious HIV
particles, but it did not affect immunoglobulins reactivity.
Vaginal fluid sampling
Three differrent collection methods were compared:
Brushing. Samples of vaginal fluids from healthy women was
obtained through extensive brushing of vaginal walls. After
sampling, brushes were rinsed in 1 mL PBS and resulting fluids
were centrifuged (1,800 g610 min) to remove epithelial cell debris
and immediately put in ice. Within 1 hour from sampling, fluids
were sterilized by filtration on 0.22 microm membranes, aliquoted
and stored at 280uC.
Cervicovaginal Lavage (CVL). Samples of cervico-vaginal
fluids (CVL) from healthy and from HIV+ Cambodian women
have been obtained through extensive rinsing of vaginal walls with
7 mL of sterile 16PBS, dispensed from a sterile syringe directly on
vaginal walls. CVL samples were completely recovered with a
sterile syringe, immediately refrigerated on ice and centrifuged
(1800 g610 min) to remove epithelial cell debris. Fluids were
sterilized by filtration on 0.22 micron membranes, aliquoted and
stored at 280uC.
Weck-Cel. This method was based on the method described
by Coombs et al [21]. Briefly, Weck-Cel sponges (Eyetec
Ophthalmic products, Altomed Ltd, UK) were pre-wet in
disposable tubes with 50 microL of sterile PBS buffer, and were
kept under flow hood, at room temperature until sampling.
Sponges were gently inserted in vagina (depth 5–7 cm) and used to
rinse throughout the mucosal surface for one minute. No special
devices, other than those routinely used in gynecological
examinations, were required for Weck-Cel application.
After sampling, sponges heads were placed back in pre-wetting
tubes, then were stored at 280‘C until processing. All sponges
were carefully weighted before and after the procedure, to
determine genital fluid recovery.
Mucosal IgA Methods
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Seminal fluids from 33 healthy donors were obtained and
processed with the standard procedure of the Centre, to minimize
any difference due to processing or maintenance [23]. Samples
from ten HIV-positive patients, known to have acquired HIV
infection by mucosal route (sexual partners of HIV-positive
patients) were collected at San Raffaele Scientific Institute.
Standard protocols require semen incubation (4uC for 1 hr) to
reduce sample viscosity, followed by dilution in sterile PBS (1:2 or
1:5), gradient centrifugation to recover spermatozoa (1800 g for
10 min), sterile filtration on 0.45 micron filters and complement
inactivation (57uC for 30 min), before freezing at 280uC. In order
to compare methods and conditions aimed at the optimal recover
of mucosal immunoglobulins, each seminal fluid was split in 16
aliquots and assayed as described below.
Female and Male fluids processing
In order to assess the optimal procedure to preserve
immunoglobulins, the efficacy of refrigeration, addition of
antibiotics, EDTA and protease inhibition were compared, as
unique additive or in double or triple association, as in the list:
a. Cryopreservation only
b. EDTA 1% V:V
c. Protease inhibitor mix 0.1% V:V
d. Antibiotic mix 2% V:V
e. EDTA 1% V:V + protease inhibitor mix 0.1% V:V
f. EDTA 1% + antibiotic mix 2% V:V
g. Protease inhibitor mix 0.1% V:V + antibiotic mix 2% V:V
h. EDTA 1% + antibiotic mix 4% V:V + protease inhibitor mix
0.1% V:V
i. USA guidelines for Mucosal Specimens Sampling and
Processing [23]
Final concentrations of reagents examined in the study were:
EDTA 0,05 M (to be diluted 1:100 V:V); a commercial cocktail of
Protease Inhibitors (IP) including pepstatin A, E64, bestatin,
leupeptin, aprotinin, to be diluted 1:1000 V:V (SIGMA-
ALDRICH Inc, St. Louis, MO, USA); Antibiotics Mix 2%,
containing Penicillin 10,000 units, Streptomycin 10 mg/mL and
amphoterycin B 25 mg/mL (SIGMA-ALDRICH).
CV fluids were split in seven aliquots and processed/added with
a different preservation protocol;
Seminal fluids were split in sixteen aliquots and were processed
to reduce viscosity and to preserve antibodies from degradation,
according to three major protocols. In the first (‘‘Immediate’’
mode), the seven reagents were immediately added to fresh semen
aliquots before any further procedure. Other seven aliquots
received the additional components at the end of the processing,
just before the step for complement inactivation (‘‘Delayed’’
mode). The remaining two aliquots, used as controls, were kept
free from additives (‘‘Null’’), or were processed according to a
published guideline (‘‘Mestecky’’ protocol) [23].
ELISA protocols for mucosal IgA/IgG/total Ig quantitation
Six different sandwich ELISA protocols were compared for
their efficacy in detecting and quantifying antibodies from mucosal
secretions. Methods were set up and compared on a panel of
immunoglobulins from genital fluids obtained from healthy people
and on standard commercial human immunoglobulins (i.e. single
or mixed IgA, IgG and IgM; IgA and IgG from SIGMA-
ALDRICH; IgM from CALBIOCHEM, Darmstadt, Germany).
All the samples were plated in double replicates. Protocols to be
compared were different in the composition of overcoating buffer
(BSA 10%+Tween 20 1% vs BSA 10%+Tween 20 5% vs skimmed
powdered milk 1%) (SIGMA-ALDRICH) and/or in the revealing
agent (biotinylated anti-human immunoglobulins + streptavidin-
HRP vs HRP-jacalin).
In detail, ELISA plates (Immuno Plate, F96 Maxysorp, NUNC,
Roskilde, Denmark) were coated with a 1:2,000 dilution of a goat
anti-human IgA-IgG-IgM (100 microl/well; KPL, Gaithersburg,
MD, USA) and incubated 2 h at room temperature. Purified CVL
antibodies and reference standard immunoglobulins (4 nicrog/
mL), diluted in the overcoating buffer on a 1:2 basis, were plated
and allowed to react overnight at 4uC.
After extensive washing with PBS 1x-Tween 20 0.1%, plates
were incubated 1 h at room temperature with the reagent to be
employed (e.g. biotinylated goat anti-human IgA diluted 1:5,000
V/V in overcoating buffer or jacalin-HRP diluted 1:500 V/V in
overcoating buffer).
ELISA plates incubated with jacalin-HRP (SIGMA-
ALDRICH) were directly revealed with commercial TMB
Peroxidase Substrate (KPL; 5 minutes of incubation before the
addition of H2SO4 and the spectrophotometric quantification at
450 nm). Sandwich plates incubated with biotinylated antibodies
(Goat anti Human IgA/IgG/IgM, SB, Birmingham, AL, USA)
required a further incubation with streptavidin-HRP, diluted
1:3,000 V/V in PBS 1x-Tween 20 0.1% buffer (1 h at room
temperature; VECTOR Laboratories, Burlingam, CA, USA)
before proceeding with the chromogen reaction.
Quantitative ELISA to measure total mucosal immunoglobulins
and IgG were carried out with the optimal protocol set for IgA
determination, employing the convenient sandwich reagents (i.e.
goat anti-human IgA-IgG-IgM or goat anti-human IgG).
Immunoglobulin purification
Affinity purification of total immunoglobulins, IgA and IgG
fractions from female and male genital fluids was carried out through
a sequential automatic chromatography system (Biologic Duoflow,
BIO-RAD Laboratories, Hercules, CA, USA), which isolated total
immunoglobulins, then IgG and finally IgA fractions from each
specimen. Three methods were compared to purify total immuno-
globulins, IgG and IgA fractions; all methods employed one, two or
three steps of chromatographic separations, such as affinity
purification on a specific antibody-bound Sepharose (total Igs, IgG
and IgA), affinity purification on Sepharose-Protein A (IgG fraction),
anionic exchange chromatography and gel filtration (IgA fraction).
Sepharose columns setting
CNB-activated Sepharose 4B (GE-Healthcare, Uppsala, SE)
was equilibrated in buffer solutions, conjugated with capture
antibodies according with manufacturer’s instructions and packed
in 2 mL or 5 mL Bio-Scale MT columns (BIO-RAD). In detail,
Sepharose columns suitable to capture total immunoglobulins, IgA
or IgG fractions were prepared from commercial rabbit antibodies
recognizing total human immunoglobulins, heavy IgA or IgG
heavy chain (SIGMA-ALDRICH). In both cases, a 1:100
proportion between resin volume and antibody solution was used;
bound was allowed, under constant stirring, for three hours at
room temperature or overnight at 4uC
After extensive washing with buffer solution, conjugated resin
columns were stored at 4uC under PBS 16 buffer containing
NaN3 0,05%.
Affinity purification of total mucosal immunoglobulins
In detail, 100 microL of genital fluids, diluted in phosphate
buffer 1x, were applied on 2 mL columns for IgA/IgG purification
Mucosal IgA Methods
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immunoglobulin elution were carried out according with standard
protocols.
Void volumes from IgA column were charged on IgG column
and processed with standard methods. Eluted fractions were
concentrated with Amicon ultra-centrifuge filter devices (Milli-
pore, Badford, MA, USA), resuspended in a small volume of PBS
16 and sterilized on 0.22 mm membranes before storage at
280uC. Concentration of recovered immunoglobulins were
determined by a comparative ELISA assay including standard
immunoglobulins dilutions, specifically set up to detect mucosal
IgA, as described below.
IgG purification by Protein G affinity chromatography
IgG fractions from genital fluids were purified by affinity
chromatography on HiTrap Protein G HP columns (GE-
Healthcare). Protein G from Group G streptococci is known for
its binding properties to IgG Fc region, but it is unable to bind IgA
and IgM antibodies [24].
In detail, Protein G columns were extensively washed and
equilibrated in PBS (1 mL/min flow) before sample application.
Sample was applied at 0.5 mL/min; the unbound fraction
containing IgA was recovered to be processed conveniently. IgG
fraction was eluted with 8 volumes of 200 mM Glycin buffer
(pH 2.0; 0,2 mL/min flow) and neutralized at pH 7.0 with 1 M
Tris-HCl buffer pH 11.0.
Columns were regenerated with two volumes of elution buffer
(1 mL/min flow) and re-equilibrated with PBS buffer (three
volumes) before starting a new purification cycle. Both unbound
and eluted fractions were added with 0.05% NaN3 and stored at
4uC.
IgM-IgA purification using anion-exchange column
chromatography
Residual fractions from IgG purification underwent IgM-IgA
purification step, performed by anion exchange column chroma-
tography. After a dialysis step in binding buffer (buffer A: 40 mM
NaCl, 20 mM TrisHCl pH 7.2), intended to change saline
concentration of the medium, fractions were applied onto the
HiTrap Q HP column (GE-Healthcare), previously washed and
equilibrated with buffer A. Unbound fractions were recovered and
stored; IgA and IgM fractions were eluted from the column with
10 volumes of buffer B (340 mM NaCl, 20 mM TrisHCl, pH 7.2).
Columns were regenerated with five volumes of buffer C (1 M
NaCl, 20 mM Tris-HCl, pH 7.2), then re-equilibrated with buffer
A (five volumes) before starting a new purification cycle. Both
unbound and eluted fractions were added with 0.05% NaN3 and
kept at 4uC.
Antibody concentration, medium change and separation
of IgA from IgM by gel filtration chromatography
Immunoglobulin fractions containing IgG and IgA-IgM anti-
bodies were concentrated on Amicon cartridges; the latter ones
were charged on the Bio-Silect SEC 400–5 column (BioRad) to
separe IgA from IgM antibodies. Columns were extensively
washed with water and equilibrated with sterile PBS buffer (7
volumes; flow: 200 microL/min). Samples were also applied and
eluted in PBS buffer (flow: 1 mL/min), and fractions containing
IgA were collected and sterilized onto 0.22 micron membranes
before storage at 280uC. Columns were extensively washed with
sterile water (7 volumes; flow: 200 microL/min), added with
0.05% NaN3 and stored at 4uC.
Affinity purification of mucosal IgA1 on jacalin-agarose
Affinity purification of IgA1 fractions from mucosal fluids was
obtained by chromatography on jacalin-bound agarose 4% beads
(SIGMA-ALDRICH), according with a protocol previously
described [25]. Jacalin is a lectin protein purified from Artocarpus
integrifolia, able to bind D-galactose; this sugar can be specifically
found in glycans on IgA1, but not on IgA2 molecules.
In detail, 3–5 mL of genital fluids, diluted in phosphate buffer
1x, were applied on 2 mL of jacalin-agarose resin, packed in Bio-
Scale MT2 column (BioRad), at 150 microL/min. After extensive
washing, IgA1 fractions were eluted with D-galactose 0.8 M
dissolved in sterile water, at 200 microL/min. Eluted antibodies
were concentrated with Amicon ultra-centrifuge filter devices
(Millipore), resuspended in a small volume of PBS 16 and
sterilized on 0.22 mm membranes before storage at 280uC.
Statistical analysis
In order to identify the condition assuring the highest
immunoglobulin recovery, two separated linear regression models
for repeated measurement - one for IgA and one for IgG (response
variable) - were fitted to compare different levels of concentration
under different experimental conditions. Since the response
variable was not normally distributed, different transformations
of data (logarithmic, square root, etc.) were tested, by the QQplot,
a graphic which relates the empirical quantiles and the quantiles of
a standard normal distribution [26]. A log-transformation of the
response variable was chosen. The regression model chosen took
into account different types of correlation between measurement
between-subject, through the specification of a particular corre-
lation matrix. In this study, a compound symmetry correlation
matrix was chosen.
The initial model, including all variables of interest (such as
experimental condition, presence of HIV infection, incubation and
interaction), was fitted. The significance of each variable was
evaluated by means of F-test. A backward stepwise procedure was
applied, to select the variables to be included in the final model. In
order to avoid false positive differences between the means of
concentration determined under different experimental condi-
tions, a Tukey adjustment for paired comparison was used [27].
All tests were two-tailed and were considered statistically
significant if the p-value associated was ,0.005. Data were
analyzed using the proc mixed of SAS Version 9.1 (SAS Institute,
Cary, NC, USA).
Results
In the first phase of this study, optimal conditions to collect and
preserve genital fluids, to isolate and to quantify immunoglobulins,
particularly IgA, were set up. Optimal assay conditions were
determined through the analysis of a cohort of male and female
Italian people, including healthy and HIV-positive individuals
(n=89).
In the second phase, methods and experimental conditions were
assayed on a cohort of Cambodian women (n=20), both HIV-
positive and healthy subjects, in order to confirm sensitivity and
reliability of results on a population characterized by a different
genetic background and possibly by a different immunologic
responsiveness to HIV. Figure 1 summarizes the design of the
whole study.
Fluid sampling and processing from female individuals
Comparison: Sampling methods. A group of 23 healthy
and a similar number of HIV-positive women underwent extensive
vaginal sampling during routine gynecological examinations. In
Mucosal IgA Methods
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concentration, naturally occurring during menstrual cycle and to
improve antibody recovery [22], sampling was carried out in the
post-ovulatory phase, i.e. 15–20 days after the first day of the latest
cycle. The use of PBS buffer at neutral pH values (pH 7.2–7.4),
although different from the vaginal physiologic pH (pH 5.5), was
not found to affect immunoglobulin recovery significantly. The
optimal volume of CVL buffer to be used was determined by a
series of preliminary sampling which employed variable volumes
of buffer (3–10 mL), according with methods previously published
[20]; 7 mL was the optimal volume that allowed a good antibody
recovery and prevented either excessive viscosity or unnecessary
dilution of the sample.
Standard sandwich ELISA assays showed that immunoglobulin
recovery was greater with CVL method than with brushing, due to
the better opportunity to reach and deterge the whole mucosal
surface. IgG recovery obtained with CVL sampling method
ranged between 10–43 microg/mL, and IgA were found between
5–21 microg/mL. Brushing gave undetectable IgG and IgA
concentrations in a high percentage of samples (10/13 samples =
76.9%); in other words, immunoglobulin concentrations were
lower than 0.125 microg/mL, that was the lower limit of assay
detection.
Weck-Cel was superior to CVL method, due to the complete
recovery of mucosal antibodies that was achieved; these results
were noteworthy, because the buffer volume recovered by CVL
was by far larger than that recovered by sponges (7 vs. 0.05 mL
respectively).
Indeed, immunoglobulin concentrations obtained with sponges
ranged between 5–128 microg/mL for IgG and between 3–
58 microg/mL for IgA, in agreement with previous observations
[15]. IgA and IgG concentrations found in each specimen were
found concordant, thus confirming that Weck-Cel sampling
methods do not introduce systematic bias in concentrations of a
single immunoglobulin type.
Comparison: Mucosal fluid preservation. Normal vaginal
bacteria, mucus and lytic enzymes from cell debris are physiologic
components of genital fluids, but they can influence antibody
recovery and evaluation. The presence of spermatozoa was also
checked by optical microscopy, although participants were asked
to avoid intercourses 24–48 hours before sampling, specimens
were controlled. However, male cells, when present, did not affect
antibody recovery and/or purification significantly (data not
shown).
Genital fluids from healthy women (HC) and from HIV-positive
patients were processed within 30 min from collection. Each
individual sample was split in multiple aliquots (brushing, CVL), or
was collected in multiple replicates (Weck-cel); one aliquot for each
individual sample was respectively added with:
a. cryopreservation only
b. EDTA
Figure 1. Design of the study. The scheme summarizes the methods tested in each step of immunoglobulins purification and quantitation.
doi:10.1371/journal.pone.0009920.g001
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d. antibiotic mix (AB)
e. EDTA + protease inhibitor mix (IP)
f. EDTA + antibiotic mix (AB)
g. protease inhibitor mix (IP) + antibiotic mix (AB)
h. EDTA + antibiotic mix + protease inhibitor mix.
Sample freezing and thawing was kept at minimum, and
samples stored for more than three months were not evaluated in
the study. In this condition, no significant association between
length of storage and sampling conditions was found. However,
IgG were more sensitive to freezing/thawing, while IgA were not
significantly affected by the event.
In order to assess the importance of quick processing,
experiments were carried out on a panel of specimens rapidly
processed (indicated as ‘‘immediate’’ mode) and on a series kept
overnight at 4uC before processing (indicated as ‘‘delayed’’ mode).
IgG concentrations from HC were at least one order of
magnitude higher than IgA ones, and ranged between 241 and
874.3 microg/mL in the ‘‘immediate’’ mode and between 221 and
682 microg/mL in the ‘‘delayed’’ mode.
IgA concentrations ranged between 214.6 and 565.6 microg/
mL (‘‘immediate’’ processing mode) and between 192.7 and
530.6 microg/mL in ‘‘delayed’’ mode. HIV-positive vaginal fluids
showed a lower concentration of IgG and of IgA antibodies,
probably due to immunocomplexes with viral proteins (range: IgG
208–678 microg/mL; IgA 18–788 microg/mL). IgA detectability
was never lost, although few individual samples showed an
occasional reduction of IgA values.
The effect of additives was compared in a statistical model
which evaluated all experimental parameters, as described in
Methods. Some variables, such as the HIV serostatus, were
excluded from the final model, because they were not influential.
Similarly, all interactions between variables, such as that between
the ‘‘type of additive’’ and the ‘‘processing mode’’, were excluded
from the final model. As shown in Table 1, the statistical model
took into evaluation the cumulative panel of data (‘‘joint’’) as well
as the hypothesis of the two comparable ‘‘immediate’’ and
‘‘delayed’’ processing modes.
According to IgG-specific statistical modeling, the use of two
additives (i.e. EDTA+IP or EDTA+AB or IP+AB) significantly
improved IgG recovery in respect to the use of single additives;
and so did the use of the triple association EDTA+AB+IP. The
double IP+AB component and the triple additive retained their
significativity after model adjustment, when analyzed in the
‘‘joint’’ model.
In the IgA statistical modeling, addition of AB was significant
both as unique component and in addition with a second agent
(AB+EDTA or AB+IP). The triple additive was significantly
superior to other protocols in the ‘‘delayed’’ mode only. No
additive retained its significativity in the adjusted model.
IgG recovery was significantly associated with the type of
additive used (F=2.27; Probability .F, 0.0306). Other variables
taken in consideration in the statistical model, such as the mode of
treatment (i.e. pre- or post-incubation addition of preserving
agents) or the HIV status (i.e. HIV-positive or -negative) were not
influential. Interaction between experimental variables, namely
between the processing mode and the type of additives, was
excluded, thus confirming the significativity of the model (F=3.72;
Probability .F, 0.0008).
IgA recovery was significantly associated with the processing
mode but not with the type of agents employed (F=19.4;
Probability .F ,0.0001). When interaction between ‘‘mode’’
Table 1. Statistical analysis of Modes and Additives in
immunoglobulin recovery from vaginal fluids.
Mode Additive IgG IgA
vs Basic Adj vs Basic Adj
Jo Null --- --- --- --- --- ---
EDTA --- --- --- --- --- ---
IP --- --- --- --- --- ---
AB Null 0.0509 --- Null 0.0061 ---
EDTA+IP Null 0.0336 --- --- --- ---
EDTA 0.0016 0.0344 --- --- ---
IP 0.0011 0.023 --- --- ---
AB 0.001 0.0026 --- --- ---
EDTA+AB EDTA+
IP
0.0084 --- Null 0.001 0.0221
--- --- --- EDTA 0.0363 ---
--- --- --- IP 0.028 ---
--- --- --- EDTA+
IP
0.015 ---
IP+AB Null 0.022 --- EDTA+
AB
0.0381 ---
EDTA+
IP
,0.0001 0.0007 --- --- ---
EDTA+
IP +AB
EDTA+
IP
0.0005 0.0111 --- --- ---
I Null --- --- --- --- --- ---
EDTA Null 0.0327 --- --- --- ---
IP --- --- --- --- --- ---
AB Null 0.0243 --- Null 0.034 ---
IP 0.0299 ---
EDTA+IP EDTA 0.0003 0.0061 --- --- ---
IP 0.0073 --- --- --- ---
AB 0.0002 0.004 --- --- ---
EDTA+AB EDTA+
IP
0.0064 --- --- --- ---
IP+AB --- --- --- --- --- ---
EDTA+ IP
+AB
EDTA+
IP
0.0015 0.0316 --- --- ---
D Null --- --- --- --- --- ---
EDTA --- --- --- --- --- ---
IP --- --- --- --- --- ---
AB --- --- --- --- --- ---
EDTA+IP IP 0.0393 --- --- --- ---
EDTA+AB EDTA+
IP
0.001 0.021 EDTA+
IP
0.0326 ---
IP+AB Null 0.0242 --- --- --- ---
EDTA 0.0173 --- --- --- ---
EDTA+
AB
0.0219 --- --- --- ---
EDTA+
IP +AB
--- --- --- Null 0.0403 ---
Modes: Jo, joint; I, Immediate; D, delayed. Additives legends: Null,
cryopreservation only; EDTA: ethylenediaminetetraacetic acid; IP, protease
inhibitors; AB, Antibiotics. Only significant P values (before and after
adjustment, Basic and Adj, respectively) were included in the Table.
doi:10.1371/journal.pone.0009920.t001
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resulted significantly associated with both the single variables
(mode: F=18.65; Probability .F ,0.0001; treatment: F=2.29;
Probability .F ,0.0280).
According with experimental observations and with statistical
analysis, the ‘‘immediate’’ processing, albeit not significant, led to
higher IgG and IgA recovery, and was therefore considered more
suitable than the ‘‘delayed’’ one. Two different additives enhanced
IgG and IgA recovery, i.e. IP+AB and EDTA+AB, respectively.
The optimal procedure therefore consisted in applying two
separate procedures for IgG and IgA to each vaginal sample to
be processed.
Fluid sampling and processing from male individuals
Normal seminal fluid is highly viscous and can not be used
directly to isolate mucosal antibodies. Moreover, it contains
endogenous lytic enzymes and cell debris that may affect antibody
recovery and evaluation. Due to its features, male fluid requires a
pre-incubation (4uC for 1 h), a proper dilution in sterile PBS, the
separation of spermatozoa by centrifugation (1,800 g for 10 min).
Finally, it also needs inactivation of complement proteins (57uC for
30 min), a procedure which enhances antibody testing and
inactivate HIV particles, if present. Addition of protease inhibitors
is also mandatory, to prevent antibody loss due to enzymatic lysis.
Protocols here described did consider optimal composition and
timing for preserving additives in comparison with a published
method [23].
Optimal sampling and storage conditions were determined by
comparing seven additives in two main modes of addition
(‘‘immediate’’ vs ‘‘delayed’’) and their controls, for a total of 16
aliquots. In the ‘‘immediate’’ mode, the seven agents (indicated
below as b–h) were added to the fresh whole seminal fluid before
any further processing, while in the ‘‘delayed’’ mode, component
addition was postponed (nine samples). Control samples were kept
untreated (a) or treated according with a published method (i, or
‘‘Mestecky’’ method)
a. cryopreservation only (negative control)
b. EDTA
c. Protease inhibitor mix (IP)
d. antibiotic mix (AB)
e. EDTA + protease inhibitor mix (IP)
f. EDTA + antibiotic mix (AB)
g. protease inhibitor mix (IP) + antibiotic mix (AB)
h. EDTA + protease inhibitor mix + antibiotic mix
i. Positive control (Mestecky method)
Comparison: seminal fluid processing. Antibody
recoveries ranged from 506.3 to 820.4 microg/mL for IgG and
from 239.63 to 455.73 microg/mL for IgA in samples processed
by ‘‘immediate’’ mode and from 436 to 665.9 microg/mL for IgG
and from 210.54 to 418.96 microg/mL for IgA in samples
undergone to the ‘‘delayed’’ mode.
Both modes were superior to the simple cryoconservation
(indicated as the ‘‘null’’ additive), that was the negative control of
the experiment. Higher IgG recoveries were achieved in the
‘‘immediate’’ mode, when components were immediately added to
seminal fluids. The ‘‘immediate’’ IgG recoveries were also superior to
those obtained with the positive control protocol (Mestecky method).
Similarly, IgA recoveries were higher in ‘‘immediate’’ samples.
Comparison of median values and of maximal immunoglobulin
concentrations, summarized in Table 2 and in Figure 2, showed that
addition of IP alone or of the triple additive achieved the higher IgG
recovery, as shown by the higher median and maximal values observed
in the ‘‘immediate’’ mode. Similar considerations could be drawn for
IgA recovery, which was maximal when the triple additive was used.
The comparison of seminal fluids from healthy donors with
those from HIV-positive cohort showed that HIV serostatus did
not affect antibody recovery significantly, therefore, this variable
was excluded from the statistical model.
Table 2. Statistical analysis of Modes and Additives in
immunoglobulin recovery from seminal fluids.
Mode Additive IgG IgA
vs Basic Adj vs Basic Adj
I Null --- --- * Null ,0.0001 *
EDTA Null ,0.0001 * Null ,0.0001 *
IP Null ,0.0001 * Null ,0.0001 *
AB Null ,0.0001 * Null ,0.0001 *
EDTA+IP Null ,0.0001 * Null ,0.0001 *
EDTA+AB Null ,0.0001 * Null ,0.0001 *
IP+AB Null ,0.0001 * Null ,0.0001 *
--- EDTA 0.0463 * --- --- ---
--- AB 0.0005 * --- --- ---
EDTA+
IP +AB
Null ,0.0001 * Null ,0.0001 *
--- --- --- --- EDTA 0.0043 *
--- --- --- --- IP 0.0041 *
--- AB 0.0236 * AB 0.0163 *
--- --- --- --- EDTA+
IP
0.0284 *
D Null --- --- --- --- --- ---
EDTA Null ,0.0001 * Null ,0.0001 *
IP Null ,0.0001 * Null ,0.0001 *
--- --- --- EDTA 0.1560 ---
AB Null ,0.0001 * Null ,0.0001 *
--- --- --- IP 0.0131 *
EDTA+IP Null ,0.0001 * Null ,0.0001 *
EDTA+AB Null ,0.0001 * Null ,0.0001 *
--- --- --- IP 0.0367 *
IP+AB Null ,0.0001 * Null ,0.0001 *
--- --- --- IP 0.0118 *
EDTA+
IP+AB
Null ,0.0001 * Null ,0.0001 *
EDTA 0.0373 * EDTA 0.0005 *
IP 0.0016 * IP ,0.0001 *
AB 0.0265 * AB 0.0009 *
--- --- --- EDTA+
IP
0.0001 *
EDTA+AB 0.0072 * EDTA+
AB
0.0061 *
--- --- --- IP+AB 0.0017 *
Mestecky Null ,0.0001 * Null ,0.0001 *
Modes: I, immediate; D, delayed. Basic, basic model; Adj, adjusted values.
Additives legends: Null, cryopreservation only; EDTA:
ethylenediaminetetraacetic acid; IP, protease inhibitors; AB, Antibiotics. Only
significant P values were included in the Table; asterisks indicated P values
maintaining their significativity after model adjustment (Adj).
doi:10.1371/journal.pone.0009920.t002
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additives obtained significant differences (p,0.05) in respect to
negative control (cryoconservation only, indicated as ‘‘null’’); some
additives or their associations were also found significantly
superior to others. In detail, the association IP+AB was found
significantly superior to addition of single components for IgG
(‘‘immediate’’ mode), and for IgA (‘‘delayed’’ mode). Similar
results were observed with the triple association EDTA+IP+AB,
which was found superior to all single components and to at least
two out of three double additives. The positive control method was
uniquely superior to negative control, but was not found superior
to any of the other additive tested.
Both the experimental observations (mean Ig values), shown in
Figure 2, and the statistical analysis confirmed that ‘‘immediate’’
addition of IP+AB was the method more suitable to enhance IgG
recovery (mean value: 919.85 total mg), while the triple
combination (EDTA+AB+IP) provided higher amounts of IgA
(mean value: 371.36 total mg). These two additives were therefore
used in sample processing before setting of methods for antibody
purification.
Setting of sandwich ELISA assay
Female and male genital fluids were used to set up the optimal
protocol of a IgA-specific sandwich ELISA assay. A sandwich
ELISA method suitable to detect mucosal IgG and especially IgA
needs high specificity and sensitivity, in order to ignore
contaminant within genital fluids and to reveal also low IgA
concentrations.
Six different protocols were compared in the study; they were
different in coating conditions, in immunoglobulin detection and
in signal amplification, as summarized in Figure 3. Jacalin was
not used in the protocol #6 because of its binding to milk, that was
likely to reduce test specificity. All protocols were compared with
the protocol #1, which was the standard method to detect serum
IgA. Standard dilutions of human IgA (1:1-1:32), ranging from
4 mg/mL to 0.125 microg/mL, were included in the analyses and
compared with similar dilutions of mucosal fluids.
The intra-assay variability was standardized by performing two
replicates for each sample dilution; each value was compared to
the standard curve. The inter-assay variability was controlled by
standardizing the experimental values on the reference IgG and
Figure 2. Immunoglobulin concentration in seminal fluids from Italian men. Box plot summarizes the immunoglobulin concentrations
(median and range) observed in seminal fluids from healthy donors, according to the Additives (cryopreservations only, single, double or triple
additives) and the Processing Modes (addition of preserving agents made pre- or post-fluid incubation). All specimens were immediately processed
after sampling; the values are given in microgram/mL. Panel legends: A. IgG range in pre-incubation samples; B. IgG range in post-incubation
samples; C. IgA range in pre-incubation samples; D. IgA range in post-incubation samples. Additives legends: Null, cryopreservation only; EDTA:
ethylenediaminetetraacetic acid; IP, protease inhibitors; AB, Antibiotics. Box legends: Box short sides represent the third (Q3) and the first quartile
(Q1), respectively, while the asterisk (*) within the box indicates the mean and the horizontal bar (--) shows the median value, respectively. Vertical
lines above or below the box indicate the corresponding quartile value (Q3 or Q1) plus or minus 1.5 times the interquartile interval (IQ=Q32Q1).
doi:10.1371/journal.pone.0009920.g002
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plate.
Detection Specificity. In order to assess specificity of
commercial reagents used to detect IgA and IgG in the
sandwich ELISA assay, a preliminary experiment of cross-
detection was performed in two replicas. Standard curves of IgA
and IgG dilutions (1:1-1:10
5) ranging from 4 microg/mL to
40 picog/mL were revealed in sandwich ELISA tests using either
anti-human-IgA or anti-human-IgG conjugated antibodies.
Moreover, antibodies from two different providers were
compared in the experiment (DAKO, Glostrup, Denmark, and
Southern Biotech, SB, Birmingham AL, USA); finally we chose
reagents from SB, due to their lower background and the higher
analytical reproducibility. Anti-immunoglobulins from other
providers were not assayed in the study. Results, summarized in
Table 3, showed that IgG-IgA cross-reactivity was uniquely
observed at high concentration of standard antibodies (i.e. at the
first two dilution points of the dilution scale).
Comparison: Sandwich ELISA Specificity and Sensi-
tivity. The six sandwich ELISA protocols to be tested were
compared on different aliquots from 18 genital fluids from healthy
donors and on an equal number of samples from HIV-positive
people (females, n=13; males, n=5 in both groups). Each aliquot
underwent a different protocol, so that the genital fluids from each
donor were analyzed in all conditions. In most protocols, IgA
resulted undetectable or the assay background prevented the
evaluation of results. In protocol #1, the mean IgA concentrations
from female fluids were 103.4 microg/mL (range: 6–250 microg/
mL) in healthy people and 219.3 microg/mL (range: 4–
780 microg/mL) in the HIV-positive cohort; protocol #6 even
achieved higher IgA mean values, that were 297.1 microg/mL
(range: 16.6–687 microg/mL) in the healthy cohort and
682.9 microg/mL (range: 11.1–2692.1 microg/mL), in the HIV-
positive group, respectively. High IgA concentrations from seminal
fluids were also obtained with protocol #6, with IgA mean values,
353.02 microg/mL (range: 21.6–453 microg/mL) in the healthy
cohort and 582.9 microg/mL (range: 25.2–1192.2 microg/mL),
in HIV-positive group, respectively. The two populations (healthy
and HIV positive subjects) did not show significant differences in
antibody concentrations.
Protocols employing BSA in coating buffer (#2-#5) showed
higher aspecific binding than the milk-based protocols (#1 and
#6); The increase in the concentration of Tween 20 detergent (1%
vs 5%), evaluated in the protocols #2-#4 and #3-#5,
respectively, was unable to control test aspecificity. Skimmed milk
indeed enhanced the specific binding of antibodies, as shown by
the comparison of protocols #1 (the control method) and #6.
Jacalin-HRP detection (protocols #2 and #4) provided a lower
sensitivity than the use of conjugated anti-human immunoglobu-
lins and biotin-streptavidin amplification (protocols #1, #3, #5
and #6). Conversely, the increased timing of antibody capture
(from one hour to overnight) enhanced test sensitivity.
In conclusion, the combination of reagents and parameters set in
the protocol #6 provided the higher specificity and sensitivity among
the conditions evaluated, and it also offered a significant improve-
ment of the standard method (#1) to detect IgA in genital fluids.
Immunoglobulin recovery
Four protocols for IgG and IgA purification were compared in
the study. As summarized in Figure 4, methods consisted in the
Figure 3. Sandwich ELISA assay. The scheme introduces the six sandwich ELISA protocols that were compared in the study.
doi:10.1371/journal.pone.0009920.g003
Mucosal IgA Methods
PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9920Figure 4. Affinity purification of immunoglobulins. Comparison of the four chromatographic methods for immunoglobulin isolation that were
evaluated in the study.
doi:10.1371/journal.pone.0009920.g004
Table 3. Cross-reactivity of commercial anti-human IgA and IgG reagents used in sandwich ELISA assays.
Anti Human
serum #1 IgA IgG
(from DAKO) 1 1.10 1:100 1:1,000 1:10,000 1:100,000 1 1.10 1:100 1:1,000 1:10,000 1:100,000
Anti-IgA 2,0496 1,9036 1,7336 6466 1546 676 1,4506 4946 1336 376 266 296
32 42 48 37 28 20 45 39 22 21 26 24
Anti-IgG 8156 3046 1016 536 236 156 1,9396 1,9916 1,9656 1,7016 9186 4206
50 45 25 28 24 21 48 43 37 40 34 47
Anti Human
serum #2
IgA IgG
(from Southern
Biotech)
1 1.10 1:100 1:1,000 1:10,000 1:100,000 1 1.10 1:100 1:1,000 1:10,000 1:100,000
Anti-IgA 1,9476 1,9466 1,5726 6276 1646 906 1,4496 4696 1206 376 216 336
53 48 46 49 36 20 42 47 35 31 24 27
Anti-IgG 8096 3016 1056 406 206 106 1,9256 1,9986 1,8936 1,7046 9666 4676
45 43 38 30 28 27 46 55 51 48 40 32
Dilutions: 1:1=4 microg/mL; 1:10=400 ng/mL; 1:10
2=40 ng/mL; 1:10
3=4 ng/mL; 1:10
4=400 pg/mL; 1:10
5=40 pg/mL. Response variability was also reported in the
Table.
Results are expressed in OD values.
doi:10.1371/journal.pone.0009920.t003
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the two-step, IgG and IgA separation on sequential columns; the
three-step, IgG affinity separation, followed by IgA isolation by
ionic exchange plus gel filtration; the IgA1 affinity separation on a
jacalin-agarose column. Assays were carried out on a panel of
aliquots from ten female and seven male genital fluids. In this way,
fluid from each donor underwent all purification protocols under
assay.
In order to rule out any systematic method bias that could limit
IgA recovery, standard human IgA and IgG were mixed at
concentrations similar to those observed in normal serum and
applied on columns. Both standard IgA and IgG from the mock
sample were fully recovered and no residual immunoglobulins
were detected in elution buffer.
Due to the peculiar composition of genital fluids, various
interfering components, such as mucin and glycoproteins, were
likely to interfere with column purification. The hypothesis of
interference was addressed by purifying both sera and genital
fluids from two individuals under the same experimental
conditions. Serum IgA were higher than the mucosal counterparts;
moreover, several small-volume elution cycles were required to
recover mucosal antibodies, a confirm of the fact that the affinity
purification of mucosal antibodies requires peculiar conditions to
be accomplished.
Neither interfering proteins or glycosylated moieties affected
male and female fluid purification. No further adjustments or
supplementary steps were added to the protocols to process male
and female genital fluids; finally, statistical modeling was not
required to compare the four sets of results.
One-Step, total Immunoglobulin affinity purification.
The assay employed sepharose affinity columns carrying
commercial antibodies recognizing human IgG, IgA and IgM, to
set up optimal conditions to capture total Ig from genital fluid
specimens. Immunoglobulin-conjugated sepharose (5 mL)
completely retained antibodies from 20–100 microL of vaginal
or seminal fluids; however, the efficiency of elution from the resin
and the antibody yield were not reproducible in different
purification sessions (range: 107–328 microg of total Ig per mL
of sample). IgA fraction was poorly eluted from total Ig fractions.
Moreover, the capturing anti-human antibodies were detached
from the resin following repeated cycles of elution: this was a
control procedure carried out on columns devoid of sample. Most
importantly, detached capture antibodies reached non-negligible
concentrations, that were higher than the cut-off values stated for
the quantitative ELISA assay. Due to these drawbacks, the one-
step purification of total immunoglobulins was considered
unfeasible to obtain mucosal antibodies.
Two-step, IgG- and IgA-specific affinity purification.
Two-step purification consisted in a tandem IgA-IgG separation,
done by loading genital fluids on IgA-capturing and subsequently
on IgG-binding sepharose columns. As observed in the one-step
method, 100 microL was the optimal fluid volume to be loaded
onto 2.4 mL columns both for female and male specimens.
Immunoglobulins yields ranged between 135–1,444 microg of IgG
per mL of sample and ,0.125–125 microg of IgA per mL of
sample, respectively. The proportions of recovered IgA were lower
than those of IgG antibodies, a finding that could be related to the
higher IgG concentration observed in genital fluids. Furthermore,
IgA recovery was not reproducible in different sessions, even when
aliquots from the same mucosal specimen were purified. Different
experiments were performed to overcome this limitation and set
upthe method conveniently.
In order to rule out that under-reactivity or cross-reactivity
might have affected ELISA detection, both eluted and antibody-
void fractions underwent ELISA testing and were detected with
both anti-IgA and anti-IgG antibodies. The anti-IgA reagent failed
in detecting IgG antibodies purified from the column, therefore
showing no reagent cross-reactivity and no accidental IgA
presence. Conversely, the anti-IgG antibodies showed a weak
cross-reactivity to eluted IgA. As expected, the anti-IgA reagent
was not reactive with antibody-void volumes from IgG column
(presumably devoid of IgA); unexpectedly, the anti-IgG reagent
failed in detecting the IgA-void volume from IgA column, which
was still containing IgG. This lack of reactivity was not due to IgG
shortage in the fluid, because this material regularly yielded IgG,
once loaded on the IgG-specific column. Moreover, all mucosal
fluids assayed, but not sera tested as controls, shared this effect; it
was finally attributed to an interfering component, presently
undetermined, that was uniquely present in mucosal fluids.
Due to the multiple drawbacks that were encountered in all
phases of the two-step affinity purification, this method was
considered unsuitable to isolate mucosal immunoglobulins.
Three-step IgG and IgA affinity column purification. In
the three-step purification method, genital fluids were first loaded
on sepharose-Protein G columns, in order to obtain IgG fractions.
Subsequently, unbound IgM and IgA were recovered as a whole
fraction, on a resin column for anionic-exchange, after the second
step of the method. After the concentration of the fraction, the gel
filtration on Bio-Silect columns led to isolate IgA from IgM.
Figure 5 shows three representative chromatograms, where
recovery of IgA subfractions is reported. In the three-step method,
3–5 mL of female or male fluids were the optimal volumes to be
loaded onto 1 mL columns. Despite the labour required to
accomplish all phases of the protocol, IgG and IgA yields were
Figure 5. Immunoglobulins purification from vaginal fluids. Panel legends: A. IgG purification by Protein G column. B. IgA purification by
ionic exchange column. C. IgA subtypes isolation by gel filtration.
doi:10.1371/journal.pone.0009920.g005
Mucosal IgA Methods
PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e9920higher than those obtained by the other protocols previously
assayed. Immunoglobulin ranges were, respectively: IgG, 100–
1,400 microg/mL of sample (after Protein-G chromatography);
IgA, 11.2–438 microg/mL of sample (after anionic exchange
chromatography); after gel filtration chromatography, IgA ranges
were similar to the previous ones, with a reduction of 10%.
Immunoglobulin recovery was not affected by immuno-
complexes, because the first purification step, performed in
Glycine buffer pH 2.0, prevented their formation. Notably, the
three-step purification yielded more reproducible results than the
other methods tested, and therefore it was chosen to isolate
immunoglobulins in the study.
One-step IgA1 Jacalin-agarose affinity purification.
Jacalin weights 54/65 kDa and contains four identical subunits,
able to bind D-Galactose belonging to O-linked carbohydrate
chains found on IgA1 and on other glycoproteins. Due to its
properties, jacalin has been used to purify mucosal
immunoglobulins since 1987 [25].
Agarose-bound jacalin specifically captures monomeric, dimeric
and secretory IgA1 molecules, and can separate these molecules
from IgA2, IgG, IgM, IgD, IgE and from the secretory component
(SC), either free or bound to J chain. IgA1 is an immunoglobulin
subtype that is specifically elicited in response to viruses, while the
IgA2 subtype takes part in the antibacterial response. Moreover,
IgA1 antibodies are largely predominant in female genital fluids
during the post-ovulatory period, while IgA2 are negligible or even
absent [16].
After elution from the agarose-jacalin column, the rates of
antibody recovery were determined by sandwich ELISA and
compared with antibody concentrations determined in IgA-void
volumes. Jacalin purification was very specific, due to the weak
OD values observed when ELISA assays were developed with
anti-IgG antibody; these OD values fell within the cut-off values at
second/third sample dilution. Previous experiment already
showed that the anti-human IgG reagents used in the ELISA
assay cross-reacted with IgA immunoglobulins found in eluted
buffers (see the ‘‘ELISA assay’’ section for details). As a further
confirmation of jacalin specificity, high concentrations of IgG were
found in IgA-void volumes, because mucosal IgG were not bound
by the lectin.
The incubation temperature did not affect the immunoglobulin
binding to jacalin significantly, while prolonged incubation
intervals (i.e. overnight contact) increased the immunoglobulin
yield from female genital fluids; this result, observed both in HIV-
positive and healthy specimens, was confirmed by ELISA assays
performed on void volumes.
The anti-IgA reagents used to develop the ELISA assays cross-
reacted with IgG found in IgA-void volumes (see the ‘‘ELISA
assay’’ section for further details). This anti-IgA reactivity to IgA-
void volumes was not due to residual IgA2 immunoglobulins: as
mentioned above, this antibody subtype is rare, if any, in post-
ovulatory vaginal specimens, and can not be bound by jacalin.
Indeed, the observed reactivity was due to IgG; when IgA-void
volumes from the jacalin column underwent a purification cycle
on the IgG-specific column, both anti-IgG and anti-IgA signals on
the resulting immunoglobulin-void volumes were abolished.
Comparison: antibody affinity purification vs ionic
exchange vs jacalin chromatography. Parallel, comparative
experiments of genital fluid affinity purification on sepharose-anti-
IgA and on jacalin-agarose columns were performed on a panel of
20 genital fluids, obtained from ten healthy women and ten HIV-
positive patients.
The comparison of median and maximal values, presented in
Figure 6, showed that both IgA and IgG were more efficiently
recovered by the three-step method. Although the use of Jacalin
gave better results, at least in the recovery of a single subtype of IgA,
the superiority of the three-step procedure resided in its higher and
more reproducible recovery of IgG antibodies. Fractioned elution
by ionic exchange allowed the effective and quantitative separation
of IgA sub-fractions, such as dimeric and monomeric IgA and J
chains, as shown by the chromatogram presented in Figure 5,
panel C. A difference in the relative concentrations of monomeric
and dimeric sIgA was observed in the course of HPLC purification;
however, the variabilityinconcentrationofthevarious IgA subtypes
was not addressed in these experiments.
Presented results also confirmed that IgG are more abundant
than IgA in the female and male genital fluids; in detail, the IgA1
subtype was found in both genital fluids. In detail, the mean IgG
levels found in IgA-depleted fractions were 142.2 (range 45–321)
vs mean IgA 72 (range 41.5–100) microg/sample (Table 4); their
concentrations were in agreement with data previously reported.
Total IgA were also evaluated in IgA1-depleted fractions, and the
mean of total IgA was 15.5 (range ,0.125–469) microg/sample.
Similar results were obtained with seminal fluids (data not shown).
Either preserving procedures, chemical addition and other
phases of immunoglobulins purification did not affect the avidity
and specificity of antibody binding; indeed, immunoglobulins from
HIV-positive specimens conserved their anti-HIV reactivity when
assayed in commercial ELISA kits (data not shown). Method
reproducibility on individual specimens was assessed on three
individual samples (three female and three male genital fluids).
Each specimen was split in three aliquots and the three series were
processed with the optimized protocols in three different
purification rounds (data not shown). Differences in IgG and
IgA values were found not statistically significant.
Method reproducibility: Italian vs Cambodian HIV cohorts
The vaginal fluids from a cohort including healthy females (not
sex workers) and HIV-positive Cambodian female sex workers
(n=20) were purified and analyzed with the methods previously
set up; results were compared to those obtained from the Italian
cohorts of healthy donors and HIV-positive subjects (males and
females) which were used to set up optimal assays conditions. This
experiment was aimed at confirming the feasibility and reproduc-
ibility of our methods on a cohort of healthy and HIV-positive
individuals endowed with a different genetic background.
Due to the local sampling practice, mucosal fluids from
Cambodian women were obtained by cervico-vaginal lavage
(CVL), and sandwich ELISA was performed as described in
Protocol #6; however, mucosal antibodies were purified by the
three-step chromatographic method previously described.
The mean IgA values were respectively 86.6 microg/mL (range:
8.4–262.16 microg/mL) for healthy women and 156.2 microg/mL
(range: 30–379.2 microg/mL) for HIV-positive patients. Immuno-
globulinvalueswerelowerthan thoseobserved inthe Italian cohort,
which were, 297.1 microg/mL (range: 16.6–687) and 682.9 mi-
crog/mL (range: 11.1–2,692.1 microg/mL), respectively. The
methods applied, especially the protocol #6 for sandwich ELISA,
confirmed their sensitivityalsointhis cohort,that showed a different
immunogenetic background and a different responsiveness to
infection. In fact, the comparison between Italian and Cambodian
cohorts, summarized in Table 4, shows a lower antibody presence
in vaginal fluids from the latter population.
Discussion
Mucosal districts of the genital tract play a key role in protection
from STD and HIV infection, due to their involvement in both
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innate and adaptive mucosal responses could prove valuable in
studying resistance to sexually transmitted infections and to HIV;
however, many attempts achieved puzzling results and many
findings failed to be further confirmed by scientific community.
Indeed, mucosal fluid sampling and analysis often gave conflicting
results, due to heterogeneity of cohort population enrolled in
studies as well as to the lack of uniform methods for sampling and
testing.
Large amounts of anti-HIV Igs, especially IgG, were usually
found in sera from HIV-positive people, while mucosal immuno-
globulins, especially IgA, were detected in some cohorts but not in
other; however, even when observed, IgA were seldom reported to
neutralize the virus [28]. Conversely, mucosal, neutralizing IgA
were found in genital secretions from HIV-exposed, seronegative
people (ESN); some studies failed in detecting such IgA. It is
believed that the higher virus exposure might be related to a
stronger mucosal response: in some cohorts, up to 70% of enrolled
Table 4. Mucosal IgA and IgG, from female genital fluid.
Sepharose-anti-Ig columns Agarose-Jacalin column (IgA1)
IgA IgG IgA-enriched, i.e. anti-IgA IgA-depleted, i.e. anti-IgG
10 IT HC ,0.125 (,0.125) 626.8 (135–1,444) 66.8 (41.5–100) 142.2 (45–321)
10 IT HIV+ 43 (,0.125–125) 839.2 (130–1627) 93.3 (16.6–252.6) 807.6 (123–3,610)
10 CA HC 54.12 (29–85) 66.84 (15.6–123.9)
10 CA HIV+ 49.62 (5.7–116) 376.52 (58.8–702)
IT: Italian; CA: Cambodian; HIV+: HIV seropositive; HC, healthy women. Immunoglobulins were obtained by immuno-affinity purification or by agarose-jacalin isolation.
Results are expressed as total micrograms, mean and range.
doi:10.1371/journal.pone.0009920.t004
Figure 6. Three-step vs jacalin affinity purification of mucosal immunoglobulins. Box plot comparing IgA and IgG immunoglobulin
purification by two different methods assayed in the study. Left panel shows IgA and IgG values measured in jacalin-bound and -excluded fractions,
respectively; right panel presents IgA and IgG values measured in the two bound fractions. Values are expressed in total micrograms per sample, in
log-scale. From the left to the right, respectively: Jacalin–agarose purification (white box): IgA from healthy controls; IgA from HIV-positive subjects;
IgG from healthy controls; IgG from HIV-positive subjects. Three-step affinity purification (grey box): IgA from healthy controls; IgA from HIV-positive
subjects; IgG from healthy controls; IgG from HIV-positive subjects. Box legends: Box short sides represent the third (Q3) and the first quartile (Q1),
respectively, while the horizontal bar (-) shows the median value. Vertical lines above or below the box indicate the corresponding quartile value (Q3
or Q1) plus or minus 1.5 times the interquartile interval (IQ=Q32Q1).
doi:10.1371/journal.pone.0009920.g006
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concentration largely depends on genetic or environmental factors,
as well as on the mode and frequency of exposure, fluid sampling
or analytical techniques. Anti-HIV antibodies account for less than
5% of the total immunoglobulins, and only a portion of binding
antibodies can actually block the virus; according to literature,
neutralizing titers of HIV-specific immunoglobulins range from 1
to 600 microg/mL [17].
In genital fluids, antibodies have different concentrations than
in serum; moreover, mucosal IgA are less abundant than IgG, that
are provided from systemic response. Due to their paucity, IgA are
therefore more prone than IgG to the risk of low recovery rates or
to the reagent cross-reactivity during assays. Among IgAs,
secretory IgA (S-IgA) is the dominant isotype in most mucosal
secretions, and displays several advantageous features when
compared to IgG and IgM [29]. Locally-produced S-IgA is
composed of polymeric IgA associated with J chain and SC
components, acquired during selective and active epithelial
transcytosis [30]. Unlike IgG or monomeric IgA, S-IgA is
especially resistant to endogenous and exogenous (bacterial)
proteolytic enzymes, which are abundant in the GI tract, in the
oral cavity, in the respiratory tract, as well as in CVL fluids and
semen. Genital proteases promptly digest IgM and IgA monomers,
but have little effect on S-IgA [31]. Due to their peculiar feature,
IgAs have not only the potential to neutralize free viruses in sera
and external secretions, but also to block viruses present within
epithelial cells [30]. The specific role of mucosal IgA in HIV
protection is still under discussion, and the marked differences
observed among various cohorts and in different laboratories
undoubtedly contributed to confusion. The lack of standardized
methods to investigate mucosal compartments is a main reason, if
not the major one, that weakens the resolution of the debate. In
fact, the definition of protective responses to HIV requires specific
know-how and experience as well as tools and methods able to
achieve solid and reproducible results in more than a single
laboratory.
In vitro, IgA reactivity may be affected by components of
mucosal fluids, e.g. mucin and glycoproteins, resulting in altered
quantitation and purification procedures; due to their lower
concentrations, mucosal IgA are more sensitive to contaminants
than IgG.
This study has systematically examined all phases of immuno-
globulins purification, from sampling to detection and quantita-
tion, has compared different methods and has considered each
step in detail, with the aim of setting a specific, standardized and
reproducible method to investigate mucosal antibodies and
especially IgA. The key point of the method here described can
be briefly summarized in the use of Weck-cel sampling for vaginal
secretion; the immediate processing of fresh semen to separe cell
fraction, and the addition to both genital fluids of EDTA and
antibiotics to prevent bacterial and/or enzymatic degradation;
protease inhibitors were found more effective in semen processing
and did not increase the recovery significantly. Three-step HPLC
column purification achieves quantitative and reproducible IgG
and IgA purification, as well as the fractioning of mono- and
dimeric IgA; further affinity purification with jacalin can split the
IgA1 and the IgA2 subfractions. Table 5 summarizes in detail the
optimal methods for all phases of purification.
Sampling method is determinant to obtain a sufficient quantity
of mucosal fluids. Weck-Cel method was superior to cervico-
vaginal lavage (CVL) and to brushing in recovering the highest
amount of fluid and therefore of antibodies [20,21].
The ‘‘immediate’’ fluid processing was more effective than the
‘‘delayed’’ mode in preserving antibodies, and was superior to
simple cryoconservation for both genital fluids. In vaginal
specimens, IgG antibodies resulted better protected by the
‘‘immediate’’ addition of single or double additives containing
antibiotics and/or EDTA; the triple additive was also effective,
and maintained its efficacy after model adjustment. Interestingly,
the addition of antibiotics and EDTA was associated to an higher
IgA concentration. The different influence of additives could
reflect a different sensitivity to proteolysis of IgG and IgA, and
suggested a major role for bacterial flora in respect to proteolytic
enzymes from vaginal fluids. In seminal samples, the triple
addition of antibiotics, EDTA and protease inhibitors significantly
improved IgA recovery in respect to the single and double
additives. The superior efficacy of the triple additive was also
confirmed in the ‘‘delayed’’ processing mode, whereas the optimal
method for seminal IgG consisted in the double addition of
antibiotics and protease inhibitors. The standard method recom-
mended in current protocols, tested in ‘‘delayed mode’’ as a
positive control, was uniquely found superior to the negative
control method, i.e. cryoconservation [23]. HIV serostatus did not
affect antibody recovery by a chemico-physical point of view;
rather, the fluids from HIV-positive individuals contained lower
quantities of IgA antibodies than those from healthy donors,
Table 5. Advices for working with human mucosal specimens and for recovering the highest level of mucosal immunoglobulins.
Seminal fluids Vaginal fluids Both genital fluids
Sampling --- Weck-Cel strips ---
Processing IgG: Immediate addition of IP+AB IgG: Immediate addition of IP+AB ---
IgA: Immediate addition of EDTA+IP+AB IgA: immediate addition of EDTA+AB ---
Detection by
Sandwich ELISA
--- --- Overcoating: Skimmed Milk 1%
--- --- Detection with biotinylated anti-human
Igs and Streptavidin-HRP
Three-step
chromatographic
purification
--- --- IgG: Sepharose-Protein-G column
--- --- IgM+IgA: Anion exchange
--- --- IgA subtypes: Gel filtration
--- --- IgA1 subtypes: Agarose-Jacalin column
doi:10.1371/journal.pone.0009920.t005
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and replication.
Sandwich ELISA assay offers higher sensitivity in detecting
mucosal antibodies, that are in lower amount than serum
immunoglobulins [19]. Assay sensitivity is a key issue for mucosal
IgA, that are in lower concentration than mucosal IgG. Due to
these reasons, the study set up a two-step method for amplification
and detection (Biotinylated-Igs and Streptavidin-HRP), that
provided higher sensitivity in respect to the direct detection with
peroxidase-conjugated jacalin. The milk-based overcoating buffer
controlled aspecific binding more effectively than the use of BSA
and detergents. Conversely, conjugated anti-sera to human Igs not
only detected mucosal antibodies under assay, but also weakly
cross-reacted with other antibody types (Table 3).
Affinity purification by jacalin-agarose offered quantitative and
reproducible recovery of the unique IgA1 fraction from genital
specimens; either the one- or the two-step immunoaffinity
columns, previously shown to work well with serum antibodies,
were poorly manageable in mucosal IgA purification [32]. The
three-step affinity purification was superior to the other protocols
assayed, despite its higher number of steps. Three steps could
appear time-consuming and might suggest a potential waste of
molecules or a higher risk of contamination, but it was not the
case. Indeed, the advantage of the method resides in the resolution
of IgA subfractions, as the monomeric, dimeric IgA and the
secretory component were easily separated and recovered. A limit
of the three-step protocol, the lack of discrimination between IgA1
and IgA2 subtypes, can be overcome by a further separation step,
carried out on a Jacalin-agarose column.
All methods and protocols set on the Italian cohorts were
applied to the analysis of a Cambodian cohort, including healthy
women and HIV-positive patients, with the aim of evaluating the
whole procedure on a different study population, endowed with a
different genetic background. Antibody concentrations were
highly different among individuals as well as between the Italian
and Cambodian populations. Both the mean and range values for
IgG were higher in HIV-positive patients, while the mean IgA
concentrations were similar, but highly variable, being distributed
over a wider range of individual values than in the Italian cohorts.
Both IgA and IgG concentrations were lower in Cambodian fluids
than in the Italian ones, irrespective of the HIV serostatus. The
sandwich ELISA assay described in the study resulted feasible to
be applied in developing countries settings, due to its high
sensitivity, to the ease of standardization and to the low cost.
Conclusion
Taken together, methods set up in this study allowed to obtain
immunoglobulins of both IgG and IgA types from specimens of
male and female genital fluids, showing to be feasible and reliable
tools for investigation of genital mucosa in general and/or of
specific local immunity to HIV. Methods here described were
successfully used in different study cohorts, confirming their
solidity, because individual or ethnic differences in immune
responsivity or humoral reactivity to infections did not affect
significantly the analysis. Without specific, standard methods for
measuring mucosal immunoglobulins, immune investigation lacks
of basic tools to study and compare local immunity, and HIV
research is severely hampered in one of its major aims, i.e. identify
and reproduce protective responses to block HIV infection just at
virus’s major portals of entry.
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